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Summary
The extracellular environment is largely comprised of
complex polysaccharides, which were historically
considered inert materials that hydrated the cells and
contributed to the structural scaffolds. Recent ad-
vances in development of sophisticated analytical
techniques have brought about a dramatic trans-
formation in understanding the numerous biological
roles of these complex polysaccharides. Glycosami-
noglycans (GAGs) are a class of these polysaccha-
rides, which bind to a wide variety of proteins and
signaling molecules in the cellular environment and
modulate their activity, thus impinging on fundamen-
tal biological processes. Despite the importance of
GAGs modulating biological functions, there are rela-
tively few examples that demonstrate specificity of
GAG-protein interactions, which in turn define the
structure-function relationships of these polysaccha-
rides. Focusing on heparin/heparan (HSGAGs) and
chondroitin/dermatan sulfate (CSGAGs), this review
provides structural insights into the oligosaccharide-
protein interactions and discusses some key and
challenging aspects of understanding GAG structure-
function relationships.
Introduction
Complex polysaccharides are primary constituents of
every eukaryotic cell surface and the extracellular envi-
ronment. Many recent studies have shown that poly-
saccharides play important roles in numerous physio-
logical and pathological processes such as growth and
development [1–5], angiogenesis and cancer [6–9], and
microbial pathogenesis [10–14]. Glycosaminoglycans
(GAGs), a major class of extracellular complex polysac-
charides, have been studied extensively [12, 15–17].
GAGs are linear acidic polysaccharides containing di-
saccharide repeat units of an uronic acid linked to a
hexosamine, and there are four classes of GAGs based
on the different chemical structures (Table 1). Each
GAG backbone can be modified by sulfation at the uro-
nic acid and hexosamine (Table 1), making them highly
information dense. For example, HSGAGs could poten-
tially contain up to 48 disaccharide building blocks
based on the sulfation pattern, which can be con-*Correspondence: rams@mit.edutrasted with that of DNA (4 building blocks) and pro-
teins (20 building blocks).
The high information density of GAGs in terms of
their sequence diversity arises from their biosynthesis,
which is a complex non-template-driven process in-
volving several enzymes with tissue-specific isoforms
[16, 18]. HSGAGs and CSGAGs are O-linked to a Ser-
Gly/Ala-X-Gly consensus motif on a core protein (GAG
and protein together known as proteoglycan). Hyaluro-
nic acid is the simplest of the GAG structures contain-
ing an unsulfated backbone (Table 1) and it is not syn-
thesized from the core protein. The biosynthesis of
HSGAGs and CSGAGs begins with the attachment of
a tetrasaccharide linker GlcAb1-3Galb1-3Galb1-4Xylb1-
O-(Ser) transferred to the core protein by four differ-
ent enzymes. The actual chain building begins after
this step where a multidomain glycosyltransferase
GlcNAcT-II or GalNAcT-II successively transfers GlcA
and N-acetyl-glucosamine (for HSGAG) or -galacto-
samine (for CSGAG), respectively, to the precursor
chain leading to chain elongation.
After the elongating chain matures to a particular
stage, it is acted upon by several enzymes, for example
sulfotransferases (distinct for HSGAGs and CSGAGs)
[16, 18] that respectively epimerize GlcA to IdoA and
sulfate the backbone. For example, one of the first
modification steps in HSGAGs is the action of the
N-deacetylase N-sulfotransferase that results in –[G-
HNS]– units from –[G-HNAc]–. This modification is fol-
lowed by the action of the C5 epimerase enzyme, which
converts some of the GlcA to IdoA. During chain matu-
ration, the 2-O, 3-O, and 6-O sulfotransferases sulfate
the monosaccharides of the HSGAG chain at different
positions. The sequence diversity of a GAG chain is
governed by the expression of these enzymes (and
their tissue-specific isoforms) and their distinct sub-
strate specificities. The action of the biosynthetic en-
zymes gives rise to regions of distinct sulfation patterns
in different GAG chains. Heparin, which is primarily syn-
thesized in mast cells, is comprised of long regions of
a homogenous trisulfated disaccharide repeat –[I2S-
HNS,6S]– interspersed with smaller variable regions con-
taining GlcA and lower sulfation. Thus most of heparin
is homogenous with fully sulfated disaccharide units.
On the other hand, heparan sulfate is synthesized by
the cell types and possesses a higher degree of tissue-
specific variation in the regions of sulfation. Thus, by
utilizing this complex biosynthetic machinery, the cell
can maintain a diverse set of GAG chains on the cell
surface and thus dynamically change its environment
in response to biochemical signals.
The chemical heterogeneity of HS/CSGAGs in terms
of their sulfation pattern and backbone chemical struc-
ture facilitates binding to a variety of proteins such as
growth factors, enzymes [12, 15, 17, 19], and morpho-
gens [2, 4, 5, 17], and also proteins on microbial patho-
gens [10, 11, 13] in the extracellular environment (Figure
1). The emerging view is that there is specificity in these
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268Table 1. Different Classes of GAGs and Their Disaccharide Building Blocks
Category Disaccharide U H Modifications
Heparin/Heparan U2X (α/β1,4) HNY,3X,6X (α1,4) IdoA/GlcA Glucosamine X, sulfated; Y, acetylated/
(HSGAG) sulfated
Chondroitin (CS)/ U2X,3X (α/β1,3) IdoA/GlcA Galactosamine X, sulfated; 3-O, sulfated
Dermatan (DS) (CSGAG) HNAc,4X,6X (β1,4) only for GlcA
Keratan Gal6X (β1,4) HNAc,6X (β1,3) Gal Glucosamine X, sulfated
Hyaluronic Acid GlcA (β1,3) HNAc (β1,4) GlcA Glucosamine None
Monosaccharide Structures
α-L-iduronic acid β-D-glucuronic acid β-D-galactoseα-D-glucosamine β-D-galactosamine X = H or SO3− X = H or SO3− X = H or SO3−X = H or SO3− N-acetylated
Y = COCH3 or SO3− X = H or SO3−
IdoA or I, α-L-iduronic acid; GlcA or G, β-D-glucuronic acid; H, either α/β-D-glucosamine or β-D-galactosamine depending on the GAG class;
Gal, β-D-Galactose. Acetylation [COCH3] is indicated using Ac and sulfation [SO3-] using S.HS/CS GAG-protein interactions that modulate the p
tactivities of the protein and thus affect its biological
functions [20, 21]. While the list of the known proteins g
wthat HS/CS GAGs bind to is growing, the oligosaccha-
ride sequence specificity of only a few of the HS/CS i
aGAG-protein interactions is known at this point of time.
Given the growing recognition of the important biologi- “
scal roles of HS/CS GAGs, it is important to understand
how oligosaccharide sequence motifs in these trans- h
clate into their biological roles by binding to and modu-
lating the activity of proteins. This review summarizes t
owhat is currently known about sequence-specific HS/
CS GAG-protein interactions by highlighting the well- t
characterized interactions and provides insights into
how structure and conformation of the HS/CS GAG and h
lthe protein govern the specificity of their interactions.
o
aBiological Roles of GAGs
wThe GAG chains of both the cell surface and secreted
bproteoglycans are present in an environment of various
oproteins such as growth factors, cytokines, morpho-
egens, and enzymes (proteases, protease inhibitors) in
athe extracellular environment. GAGs play a critical role
hin assembling protein-protein complexes such as growth
gfactor-receptor or enzyme-inhibitor on the cell surface
nand in the extracellular matrix that are directly involved
min initiating cell signaling events or inhibiting biochemi-
dcal pathways (Figure 1). Furthermore, extracellular
aGAGs can potentially sequester proteins and enzymes
land present them to the appropriate site for activation
((Figure 1). Thus for a given high-affinity GAG-protein
sinteraction, the positioning of the protein binding oligo-
psaccharide motifs along GAG chain determines if an
factive signaling complex is assembled at the cell sur-
gface or an inactive complex is sequestered in the mat-
mrix. It should be noted that high-affinity GAG-protein in-
bteractions are not the only biologically significant
interactions. GAGs have been shown to play important
broles in maintaining morphogen gradients across a cell
or tissue, which have been implicated in developmental hrocesses [2, 5]. Maintaining a gradient in the concen-
ration of growth factors or morphogens would involve
raded affinities between different GAG sequences
ith the given protein. Thus, the nature of GAG-protein
nteractions coupled with their sequence diversity en-
bles GAGs to “fine tune” or what can be viewed as
analog modulation” of the activity of proteins. As
tated earlier, there have been numerous studies that
ave implicated the role of GAGs in important biologi-
al processes. Summarizing all these studies is beyond
he scope of this review. Thus the recent investigations
f the biological roles of GAGs are briefly discussed in
he following.
The earliest known biological role of GAGs is that of
eparin, which has been used as a clinical anticoagu-
ant for several decades. Several studies have focused
n biochemical characterization of the anticoagulant
ctivity of heparin in terms of its specific interaction
ith antithrombin III (see below for details). The GAG
iosynthetic enzymes have been the target of numer-
us genetic studies that have provided direct functional
vidence on the involvement of GAGs in cell growth
nd developmental processes involving Wnt, Hedge-
og, transforming growth factor (TGF), and fibroblast
rowth factor (FGF) signaling pathways [5]. Murine ge-
etic studies have also directly implicated the role of
ast cell heparins in acting as a reservoir for storing
ifferent proteases [22, 23]. More recently, RNA-medi-
ted interference and deletion mutagenesis of a homo-
og of chondroitin synthase in Caenorhabditis elegans
involved in the biosynthesis of chondroitin sulfate) was
hown to cause defects in early embryogenesis [3]. The
henotypic linkage between HSGAGs and growth
actors was also identified by null mutation of the EXT1
ene in mice, which affected the morphogenesis and
idline axon guidance during development of the
rain [24].
In addition to looking at enzymes involved in GAG
iosynthesis, extracellular GAG degrading enzymes
ave also been the focus of many studies. Through
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269cloning and characterization of the human heparanase
enzyme (depolymerizes the cell surface HSGAGs),
which is secreted by tumor cells during metastasis,
these polysaccharides have been shown to be impor-
tant barriers to tumor metastasis [25, 26]. Recently, a
novel extracellular sulfatase enzyme was discovered
and was shown to play a key role in embryogenesis
through the Wnt signaling pathways [27, 28]. This was
the first time that an extracellular enzyme Qsulf1 (ho-
mologous with the lysosomal N-acetyl 6-O desulfatase)
was shown to be involved in governing the function of
HSGAGs in cell signaling.
Another approach to studying the biological roles of
GAGs has been to utilize novel constructs of proteins
for direct in situ monitoring of GAG-protein interactions.
Using such a construct of FGF receptors with alkaline
phosphatase and a ligand and carbohydrate engage-
ment assay (LACE), the regulation of FGF signaling dur-
ing mouse development by spatial and temporal ex-
pression of HSGAGs was investigated [29]. Enzymes
that depolymerize GAGs have also been used in in vivo
animal studies. By using heparinase I and heparinase
III to depolymerize cell surface HSGAGs in a mouse
model for cancer, it was shown that distinct HSGAG
fragments either promoted or inhibited tumor growth
and metastasis [7]. Chondroitinase ABC, which de-Figure 1. Structure and Biological Roles of
GAGs
GAGs present as a part of proteoglycans on
the cell surface and ECM, bind to numerous
proteins and modulate their function. Shown
in the box are the commonly occurring di-
saccharide repeat units of heparin, heparan,
chondroitin, and dermatan sulfate. The
monosaccharides are represented based on
Table 1 and the hydrogen atoms are not
shown for clarity. Regions of possible sulfa-
tion and acetylation modifications are indi-
cated with a red X and Y.polymerizes CSGAGs, has been shown to promote func-
tional recovery after glial scar injury in adult rats [1].
The studies summarized above provide direct evi-
dence of the biological roles of GAGs. However, it is
important to understand these roles from the stand-
point of structure-function relationships of GAG-protein
interactions. Delineating the physiological context of
GAG-protein interactions to truly define structure-func-
tion relationships in vivo is a challenging task. Never-
theless, there have been several approaches to both
qualitatively and quantitatively investigate in vitro GAG-
protein interactions, as summarized in a recent review
[30]. The list of proteins that are known to interact with
GAGs (Table 2) has been outlined in recent reviews [12,
15, 17, 31] and this list is constantly expanding. In the
following section, the GAG sequence specificity of
these interactions is discussed using prototypic exam-
ples of the best characterized GAG-protein systems.
Biochemical Characterization of GAG-Protein
Interactions
Growth Factors
Fibroblast Growth Factor. The FGF family of proteins
contains 23 different members and is primarily involved in
cell signaling during growth and development. The most
studied GAG-protein interactions are that of HSGAGs
Chemistry & Biology
270Table 2. GAG-Protein Interactions
Protein-GAG GAG Oligosaccharide Biological Roles
FGF-1-HSGAG –[I2S-HNS,6S]n– n>2 for binding > 5 for FGF- FGF-oligomerization, assembling FGF-FGFR
mediated cell signaling complexes leading to receptor oligomerization and
FGF-2-HSGAG –[I2S-HNS,6X]n– n>2 for binding > 5 for FGF- cell signalling. Cell growth and development,
mediated cell signaling. Sulfation at 6-O angiogenesis.
position is not required for binding but may be
required for cell signaling
HGF/SF-DS I-HNAc,4S-I-HNAc,4S-I-HNAc,4S-I-HNAc,4S Hepatocyte regeneration, morphogenesis, cell
motility, tumorigenesis and metastasis
Midkine, Pleotrophin-CS –[G-HNAc,4S,6S]n– or –[G2S-HNAc,6S]n– Neuronal adhesion, migration and neurite outgrowth
Other growth factors/
morphogens: FGFs (1–21),
TGFβ, VEGF, PDGF, EGF
Amphiregulin, Betacellulin,
Neuregulin, IGF II Activin, Sonic
Hedgehog, Sprouty peptides,
Wnts (1-13), BMP-2, 4 Cell growth, morphogenesis and development
AT-III-heparin –[HNAc,6S-G-HNS,3S,6S-I2S-HNS,6S]– Anticoagulation and antithrombosis
Annexin V-heparin –[I2S-HNS,6S]n– Antithrombosis
HCF II-DS I2S-HNAc,4S-I2S-HNAc,4S-I2S-HNAc,4S Anticoagulation and antithrombosis
Other coagulation factors: Factor Anticoagulation and antithrombosis
Xa, Thrombin, Thrombomodulin
HSV-1-heparin U-HNS-I2S-HNAc-I2S(orG2S)-HNS-I2S-HNH2,3S,6S Microbial pathogenesis
FMDV-heparin –[I2S-HNS,6S]n– Microbial pathogenesis
VCP-heparin –[I2S-HNS,6S]n– Microbial pathogenesis
Cytokines/Adhesion: Interleukins, Inflammation/immune response
GM-CSF Interferonγ, TNF-α,
Angiostatin, Endostatin
L-selectin, N-CAM MAC-1,
PECAM-1 CXC, Bac-5,7, PR-39
The GAG oligosaccharide sequences are shown for the prototypic examples of GAG-protein interactions.with basic FGF (FGF-2) and acidic FGF (FGF-1). FGF-2 is d
mimplicated in development and differentiation of several
tumors where it has been proposed to be a part of an m
autocrine loop or to induce tumor angiogenesis [6, 19].
FGF signaling involves the following steps—FGF binding t
Hto its cell surface tyrosine kinase receptors (FGFRs),
oligomerization of FGF leading to receptor oligomeriza- i
ition, phosphorylation of other signaling molecules, and
initiation of signaling cascade. HSGAGs play a critical F
trole in FGF signaling by facilitating the formation of
FGF-FGFR complexes (and/or stabilizing these com- n
aplexes) and enhancing (and/or stabilizing) FGF oligo-
merization. Several crystal structures and cocrystal F
astructures of different FGFs with HSGAG oligosaccha-
rides and FGFRs have been solved [32–35]. These crys- r
tal structures indicate that FGF-1 and FGF-2 have dif-
ferent modes of oligomerization facilitated by binding c
Dto HSGAG oligosaccharides. A single HSGAG oligosac-
charide bridges two FGF-1-FGFR complexes (2:2:1 m
hstoichiometry) with no protein-protein contact between
FGF-1 monomers. On the other hand, two HSGAG oligo- F
Hsaccharide chains bridge two FGF-2-FGFR complexes
(2:2:2 stoichiometry) once again with no protein-protein p
pcontact between FGF-2 monomers. Also, using struc-
tural analysis of the FGF-2 crystals structures and pro- t
otein engineering methods a novel dimeric FGF-2 was
constructed and shown to have significantly enhanced C
tHSGAG-mediated signaling [36]. It was also implicated
that there was protein-protein contact in this engi- t
Dneered FGF-2 dimer that binds to HSGAG oligosaccha-
rides, which was in contrast with the dimerization ob- t
rserved in the cocrystal structure [36]. These studiesemonstrate the complexity of the actual molecular
echanism involved in HSGAG-mediated FGF oligo-
erization and signaling.
The heparin-derived oligosaccharides in the cocrys-
al structures contain predominant repeat unit of –[I2S-
NS,6S]n– where n = 2, 3, 4, 5, 6. The 2-O sulfate of the
duronate and the N-sulfate of the glucosamine are crit-
cal modifications that are required for both FGF-1 and
GF-2 signaling [37]. The 6-O sulfation has been shown
o be critical for FGF-1 signaling but is not completely
ecessary for FGF-2 signaling. Typically, tetra- and hex-
saccharides are sufficient to bind with high affinity to
GF-1 or FGF-2. However, octasaccharides or longer
re required for bridging a dimeric FGF-2 along with the
eceptor to form a ternary signaling complex [34, 35].
Other GAG-Growth Factor Interactions. The biologi-
al functions modulated by the interactions of CS and
S with growth factors and cytokines have been sum-
arized in recent reviews [12, 17]. Similar to HSGAGs,
ighly sulfated DS chains have been shown to bind
GF-2 and FGF-7 (with lower affinity compared to
SGAGs) and implicated in cell growth and wound re-
air. DS has also been shown to bind and activate He-
atocyte growth factor (HGF) signaling pathway
hrough c-met receptor (protooncogene). Comparison
f HSGAG and DS interactions with two truncated
-terminal variants (NK1 and NK2) of HGF revealed that
he minimal length that binds with high affinity is a
etrasaccharide for HSGAGs and hexasaccharide for
S [38]. Oversulfated CS with specific sulfation pat-
erns in the brain CS PGs have been implicated in neu-
onal adhesion, migration, and neuritogenesis via their
Review
271interactions with pleotrophin and midkine. Similar to
the growth factor model, assembling of the pleotrophin
complexes on cell surface by CS have been implicated
in signaling, while CS on extracellular environment have
been implicated in sequestering this cytokine.
Inhibitors of Coagulation Cascade
The coagulation cascade is controlled by a group of
serine protease inhibitors including AT-III, heparin co-
factor II, tissue factor pathway inhibitor, and other
factors. AT-III is the most prominent because all of the
coagulation proteases (except factor VIIa) are inhibited
by AT-III, which forms equimolar covalent complexes
with these enzymes.
Heparin-AT-III. Heparin forms a ternary complex with
thrombin and AT-III, accelerating by 2000-fold the rate
of thrombin inhibition by AT-III, thereby preventing co-
agulation [39, 40]. AT-III recognizes a specific pentasac-
charide sequence motif [HNAc,6S-G-HNS,3S,6S-I2S-HNS,6S]
within heparin. This pentasaccharide motif, which
makes up for only 3% of all the chains in commercially
prepared heparin, binds to AT-III with a Kd z 0.6 nM
[39, 40]. The X-ray cocrystal structure of a synthetic
mimic of this pentasaccharide motif with AT-III [39] indi-
cates that the 3-O sulfate group on the glucosamine
[HNS,3S,6S] makes many ionic contacts with the protein.
This 3-O sulfation is absolutely necessary for specific
interaction between the pentasaccharide motif and AT-
III. This cocrystal structure also implicated that penta-
saccharide binding and subsequent conformational
change activates AT-III for rapid inhibition of Factor Xa.
However, chemical synthesis of heparin mimetics
have implicated that AT-III inhibition of thrombin re-
quires a much longer heparin chain of at least 16–18
monosaccharides, in addition to requiring the presence
of the pentasaccharide sequence [41, 42]. More re-
cently, the cocrystal structure of ternary complex of AT-
III-thrombin-heparin mimetic was solved [43]. This crys-
tal structure demonstrated the bridging of AT-III and
thrombin by a 16-mer synthetic mimic of a heparin con-
taining a highly sulfated poly β-D-glucose tetrasaccha-
ride at the nonreducing end followed by a stretch of
neutral poly β-D-glucose heptasaccharide and the
pentasaccharide motif at the reducing end. Thus, it is
apparent that sequence and chain length is important
for anticoagulant activity of heparin. In a recent study,
the chain length was also shown to be an important
determinant for heparin-mediated inhibition of throm-
bin by binding to heparin cofactor II. It was implicated
that heparin binding to heparin cofactor II required a
minimal chain length of 13 monosaccharides and the
complete allosteric inhibition of thombin (2000-fold
higher than without heparin) required a chain length of
26 monosaccharides [44].
Heparin-Annexin V. Exposure of phosphatidylserine
(PS) on the outer membranes of activated cells is a
physiological signal for the onset of processes such as
coagulation and apoptosis. Extracellular annexin V (a
Ca2+-dependent membrane phospholipid binding pro-
tein) recognizes this signal, binds to PS components
of the membrane, and self-assembles laterally into an
organized array. This annexin array forms a shield that
prevents excessive clot formation. A recent X-ray
cocrystal structure of annexin V with a heparin-derived
tetrasaccharide U -H -I -H suggested that2S NS,6S 2S NS,6SCa2+-mediated annexin V-heparin interactions via these
sequence motifs may facilitate the annexin self-assem-
bly process and/or stabilize the oligomeric annexin
layer [31].
DS-Heparin Cofactor II. A specific dermatan sulfate
hexasaccharide [I2S-HNAc,4S]3 has been shown to bind
with high affinity to heparin cofactor II and inhibit
thrombin [45]. This hexasaccharide has been reported
to constitute only 2% of hexasaccharides in dermatan
sulfate [45]—another example of a rare modification
having a key functional role. It has been proposed that
unlike heparin that inhibits thrombin by bridging it with
heparin cofactor II, dermatan sulfate inhibits the throm-
bin-fibrin complex via heparin cofactor II [46].
Microbial Pathogens
A growing number of pathogens, including bacteria,
viruses, and parasites, have been shown to utilize cell
surface GAGs as receptors to target their host cells. It
was shown that a heparan sulfate octasaccharide U-
HNS-I2S-HNAc-I2S[or G2S]-HNS-I2S-HNH2,3S,6S containing a
rare 3-O sulfated free amine bound to the gD glycopro-
teins of herpes simplex virus [13]. Another well-charac-
terized HSGAG-virus interaction is that of a HSGAG oli-
gosaccharide involved in binding to the virus shell
protein of the foot and mouth disease virus (FMDV). In
fact, the cocrystal structure of this oligosaccharide with
the FMDV shell protein has been solved [11]. More re-
cently, the cocrystal structure of the vaccinia virus
complement control protein (VCP) with a heparin-
derived decasaccharide [I2S-HNS,6S]5 provided valuable
insights into the regulation of the complement pathway
by pathogens interacting with cell surface polysaccha-
rides on host cells [10]. The adhesion of erythrocytes
infected by the malarial parasite to placenta requires a
low sulfated CS (G-HNAc,4S repeat unit) with a minimum
length of a dodecasaccharide [17].
Although hyaluronic acid (HA) is the simplest of GAG
families in terms of chain modification, it has been
shown to bind to many proteins at the cell-ECM inter-
face as well as in the pericellular environment [47]. HA
binding proteins are known as hyaladherins, and the
best-studied HA-protein interaction is that with CD44,
which plays a key role in cancer [48, 49].
The above examples summarize some important as-
pects of the biological role of GAG-protein interactions
in terms of specific GAG sequences. The oligosaccha-
ride motif that is recognized by a protein is often found
in low abundance. This strengthens the idea of speci-
ficity in GAG-protein interactions given the diversity of
GAG sequences. Most of these interactions involve for-
mation of multimeric complexes (self-oligomers, pro-
tein-receptor, enzyme-inhibitor, etc.) that are facilitated
by GAGs. Thus in addition to just looking at the abun-
dance of the oligosaccharide motif that binds to a spe-
cific protein, it is important to determine the position of
this motif in the context of other protein binding motifs
in a given GAG chain length. Given that different classes
of GAGs can interact with the same protein, albeit with
different affinities, there can be compensating effects.
For example, the increased abundance of FGF binding
DS GAGs can achieve the same effect of FGF binding
HSGAGs in lower abundance. On the other hand, it is
also possible that the difference in affinities between
different classes of GAGs for a given protein plays an
Chemistry & Biology
272important role in maintaining gradient in protein con- m
tcentration.
m
G
Structural Specificity of Protein-GAG Interactions f
The specificity of GAG-protein interactions is governed h
by the ionic interactions of the sulfate and carboxylate t
groups of GAGs with the basic amino acids on the pro- S
tein as well as the optimal structural fit of a GAG chain S
into the binding site of the protein. The topology and r
distribution of the basic amino acids of the GAG bind- s
ing site on the protein influences its specificity in mo- t
lecular recognition of GAG sequences. The binding af- o
finity of the interaction depends on the ability of the i
oligosaccharide sequence to provide optimal charge s
(orientation of sulfate groups) and surface (van der o
Waals contact) complimentarity with the protein, which i
is governed by the three-dimensional structure and s
conformation of GAGs. t
GAG Conformation a
X-ray fiber diffraction analyses of the different GAGs a
[50] and NMR studies [51] have indicated that the GAG g
backbone (Figure 2) adopts uniform helical structures o
where helical parameters n (the number of disaccharide W
units per turn of the helix) and h (the axial rise per di- t
saccharide) depend on the nature of the cationic
counter ions. For example, a heparin oligosaccharide i
containing the predominant –[I2S-HNS,6S]– repeat unit a
would adopt a 2-fold helical structure with n = 2 and a
lh = 8.4 Å (Figure 2). The main parameters that deter-Figure 2. Three-Dimensional Structure of GAGs
Shown in (A) is a ball and stick representation of a heparin oligosaccharide with –[I2S-HNS,6S]– repeat unit (carbon, oxygen, nitrogen, and
sulfur atoms colored gray, red, blue, and yellow, respectively). Also shown is the chair conformation of the expanded disaccharide unit where
the backbone atoms (colored red) are labeled along with the glycosidic torsion angles (f1, ψ1) and (f2, ψ2). Shown in (B) is a helical wheel
projection (i.e., viewing along the line of helical axis perpendicular to the plane of the paper) of the sulfate groups of the structure shown in
(A). Note that the heparin structure adopts a uniform 2-fold helical symmetry with n = 2.0 and h = 8.4 Å. (C) Commonly observed low-energy
ring conformations of iduronic acid (atoms colored the same way as in [A]).ine the topology of the GAG chain are the glycosidic
orsion angles (f1, ψ1) and (f2, ψ2) and the ring confor-
ation of the monosaccharides. The hexosamine and
lcA pyranose puckers in GAGs adopt a 4C1 chair con-
ormation. On the other hand, the IdoA pyranose ring
as the ability to adopt multiple low-energy conforma-
ions such as 1C4, 4C1, 2SO, and OS2 [52] (Figure 2).
tructural Implications of GAG-Protein Interactions
everal cocrystal structures of HSGAG oligosaccha-
ides with different proteins have been solved. These
tructures have highlighted the ionic interactions be-
ween specific sulfate groups and carboxylate groups
f HSGAGs with the basic amino acids in the GAG bind-
ng site on the protein. However, ionic contacts are not
ufficient to explain the optimal structural fit of a GAG
ligosaccharide to the binding site of the protein that
nfluences the affinity of the interaction. From the
tandpoint of GAG conformation, it can be envisioned
hat protein binding would induce local distortions in
n otherwise uniform helical structure of GAGs, which
re manifested as changes in the glycosidic torsion an-
les. These conformational changes would enable an
ptimal structural fit in terms of both ionic and van der
aals contact between the oligosaccharide motif and
he protein.
This structural aspect of GAG-protein interaction was
nvestigated in a recent study, where a systematic
nalysis of the helical parameters of HSGAGs in all the
vailable protein-HSGAG cocrystal structures revealed
ocal conformational changes causing a kink in the oli-
Review
273gosaccharide helical structure that directly interacted
with the protein [53]. These deviations were captured
by measuring localized helical parameters nL and hL
obtained by repeating each successive disaccharide
unit with the experimentally observed glycosidic tor-
sion angles. Thus any local deviation from the helical
structure would be reflected as significant changes in
these parameter values when compared to those of a
uniform helical structure. The observation of the oligo-
saccharide kink in the different protein-GAG cocrystal
structures is summarized below.
FGF-HSGAG Complexes. In all the cocrystal structures
of HSGAG oligosaccharides with FGF-1 and FGF-2 and
their receptors [32–35], the kink in the FGF binding oli-
gosaccharide spanned a trisaccharide [HNS,6S-I2S-
HNS,6S] where an iduronate is flanked by two glucosam-
ines (Figure 3) and it contained the critical NS and 6-O
sulfate groups on the hexosamine and 2-O sulfate
groups on IdoA implicated in high-affinity interaction
with FGFs. The sharp curvature of the kink in the oligo-
saccharide was reflected in the deviation of the hL value
from around 8.4 Å (unbound region) to around 7.6 ÅFigure 3. Kink in GAG Helical Structure
Shown in (A) is the grasp rendering of FGF-2 (pink) and AT-III (gray) cocrystal structures with HSGAG oligosaccharides (brown) where the
HSGAG binding site on the protein is in blue. Only that part of AT-III close to the pentasaccharide binding site is shown for clarity. Note the
kink in the helical axis (indicated by an arrow) from the unbound to bound structure. (B) Schematic of the two kinds of kink, sharp bend (left)
and helical overwind (right), observed in the different protein-HSGAG cocrystal structures. The oligosaccharide sequences in the cocrystal
structures are indicated under the corresponding schematic where the region of the kink is colored in red.(kink region), whereas the nL value was around 2.0
throughout the structure. The formation of the kink was
associated with changes in two specific glycosidic tor-
sion angles where change in one caused the helical
axis to bend below and change in the other caused
the helical axis to bend above the reference axis of the
unbound oligosaccharide structure, thus forming a kink.
Further, in both FGF-1 and FGF-2 bound oligosaccha-
rides, the ring conformation of the IdoA in the trisac-
charide spanning kink was in 1C4. Thus, the axial posi-
tioning of the glycosidic bonds due to the 1C4 IdoA
conformation enhanced the degree of the kink. Binding
of HSGAGs to FGFs does not induce any conforma-
tional changes on the protein. In fact, the topology of the
HSGAG binding loop regions on FGF-1, -2, -4, -7, and
-9 (whose crystal structures have been solved) almost
coincide with each other [53]. On the other hand, the
distribution of the basic amino acids in the binding
loops is different for each of the FGFs [53, 54]. Thus
the narrow binding pocket formed by the HSGAG bind-
ing loops on each FGF imposes structural constraints
on the HSGAG oligosaccharide that induce a kink for
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274optimal surface contact with the protein. The distribu- s
ttion of the basic residues within the HSGAG binding
loops imposes unique constraints on the orientation a
Vand spatial arrangement of the sulfate groups. To-
gether, these structural constraints determine the spec- r
oificity of oligosaccharide sequence to bind to different
FGFs. f
iAT-III-Pentasaccharide Complex. In contrast with FGF,
it has been implicated that binding of the pentasaccha- t
sride motif to AT-III induces conformational change that
causes widening of the heparin binding grove of AT-III t
T[39]. These conformational changes around the heparin
binding grove also lead to allosteric conformational i
mchanges leading to the expulsion of the reactive site
loop of AT-III (which is distant from the heparin binding b
osite), which enhances the binding of this loop to Factor
Xa [39]. The recently solved AT-III-thrombin-synthetic e
wheparin mimetic cocrystal structure demonstrated that
bridging of thrombin and AT-III by heparin is relatively
rinsensitive to the expulsion of the reactive site loop,
consistent with the earlier studies [43]. a
aThe kink in the AT-III bound pentasaccharide motif
[HNAc,6S-G-HNS,3S,6S-I2S-HNS,3S,6S] spanned a trisaccha- c
Hride [HNS,3S,6S-I2S-HNS,3S,6S] that contains the critical
3-O sulfate group (of nonreducing end glucosamine) re- β
pquired for AT-III binding (Figure 3). Interestingly, the kink
in the pentasaccharide is reflected by a transition in nL r
Bvalue from 2 (unbound region) to 3 (bound region). This
transition in the nL value causes helical overwind com- p
ppared to the sharp bend in the FGF-bound oligosaccha-
ride. Thus in the case of AT-III-pentasaccharide com- t
tplex, the optimal ionic and van der Waals contact with
the protein requires the overwinding of the helix of the z
tpentasaccharide, resulting in a kink. Chemical synthe-
sis of heparin mimics containing IdoA conformation t
clocked to either 1C4 or 2SO form and NMR studies have
shown that 2SO conformation of the IdoA is important i
cfor high- affinity binding to AT-III. Also NMR analysis
of the free pentasaccharide in solution indicates that s
pconformational equilibrium of the IdoA is shifted toward
1C4 . Thus the transition of the IdoA conformation to t
y2SO in the bound pentasaccharide enhances the helical
overwind to provide optimal interactions with AT-III. B
cOther Protein-HSGAG Structural Complexes. In the
other protein-HSGAG cocrystal structures, for example s
cFMDV [11], annexin V [55], NK1 domain of HGF [56],
and the most recently solved vaccinia virus comple- i
tment protein (VCP) [10], the heparin-derived oligosac-
charides predominantly contained the trisulfated disac- a
ucharide repeat unit –[I2S-HNS,6S]–. The oligosaccharide
kink in the FMDV cocrystal structure was similar to that a
oof the AT-III-bound pentasaccharide (Figure 3), in that
there was a helical overwind, the nL value going from 2
m(unbound) to 3 (protein bound). This region spans three
monosaccharides [HNS,6S-I2S-HNS,6S] with the iduronate H
win the 2S0 conformation. On the other hand, the oligo-
saccharide kink in the NK1 domain cocrystal structure t
5was similar to that of the FGF-1 and FGF-2 bound oli-
gosaccharides (Figure 3). Since annexin V was cocrys- b
Ttallized with only tetrasaccharides it was difficult to
make a meaningful interpretation of the nL and hL val- v
pues for quantifying the deviations from the overall uni-
form helical structure.
iIn the case of the VCP cocrystal structure, the kinkpans a hexasaccharide showing two distinct transi-
ions in hL values (nL was around 2), one from 8.0 to 7.3
nd the other from 7.3 to 6.3. There were two structural
CP-oligosaccharide complexes in the asymmetric unit
elated by an approximate 2-fold symmetry. The region
n the oligosaccharide that showed a transition in hL
rom 8.0 to 7.3 interacted with the other VCP molecule
n the asymmetric unit and the sharper bend (hL transi-
ion from 7.3 to 6.3) interacted with the VCP in the
tructural complex. All the IdoAs in the region spanning
he kink was observed to adopt the 2SO conformation.
he cocrystal structure studies also indicated that there
s a conformational change manifested as a hinge
ovement in the protein that is stabilized by heparin
inding. The hinge movement exposes the binding site
f VCP for proteins in the complement pathway and
nhances the slowing down of the complement path-
ay activation.
Chondroitinase B-Dermatan Sulfate Complex. More
ecently, the oligosaccharide kink was also implicated in
n enzyme-substrate complex, mainly chondroitinase B,
nd its substrate dermatan sulfate. Chondroitinase B
leaves DS oligosaccharides at the [-HNAc,4S–I-HNAc,4S–I-
NAc,4S-] linkages (cleavage sites marked with “–”) via
elimination to give U-HNAc,4S containing reaction
roducts where U is a uronic acid with 4,5 unsatu-
ated linkage. The cocrystal structure of chondroitinase
with three disaccharide reaction products of DS de-
olymerization was solved recently [57] and two of the
roducts were in the catalytic site of cleavage. In addi-
ion, the cocrystal structure also contained a Ca2+ ion
hat was coordinated by the oxygen atoms on the en-
yme as well as the carboxylate of the U of the reac-
ion product in the catalytic site. Based on the interac-
ions between the active site amino acids and the Ca2+
oordination, the conformation of the intact substrate
n the active site was modeled based on the two disac-
haride reaction products. Analysis of the final sub-
trate conformation indicated that there was almost a
erpendicular local bending of the DS helical structure
o position the substrate in an optimal fashion for catal-
sis. In fact, the cocrystal structures of chondroitinase
with GlcA containing CS oligosaccharides [57] indi-
ated that the substrate did not occupy the catalytic
ite completely. This was due to the inability of the rigid
hair conformation of GlcA to accommodate the bend-
ng of the oligosaccharide. Thus the topology and dis-
ribution of basic amino acids of the chondroitinase B
ctive site and the Ca2+ ion coordination imposes
nique structural constraints in terms of sulfation pattern
nd conformation of the substrate that was satisfied
nly by an IdoA containing DS substrate.
NMR studies have implicated that the overall confor-
ation of HA in solution is flexible and this flexibility of
A is implicated to assemble different hyaladhereins
here each protein captures distinct conformations of
he different oligosaccharide binding motifs in HA [47,
8]. However, there are no cocrystal structures of HA
inding proteins complexed with HA oligosaccharides.
hus availability of these crystal structures would pro-
ide better structural insights into the specificity of HA-
rotein interactions.
From the examples discussed above, it is becoming
ncreasingly evident that the propensity of GAG oligo-
Review
275saccharides to form distinct kinks in their otherwise
uniform helical conformation provides a structural sig-
nature or molecular recognition motif for sequence
specific protein binding. This kink in the GAG oligosac-
charide is reminiscent of DNA kink upon binding to pro-
teins (such as transcription factors, restriction endonu-
cleases, etc.), a hallmark for regulating the specificity
of DNA-protein interactions. Protein binding induces
distinct conformational changes to the sugar phos-
phate backbone of DNA leading to the kink formation.
Although more restrictive compared to the multiple ring
conformations sampled by IdoA in GAGs, the ribose
sugar pucker can also adopt different ring conforma-
tions such as 2# endo and 3# endo.
Based on the examples discussed above, one would
imagine that the conformationally flexible IdoA is nec-
essary for formation of the kink. However, it should be
noted that the kink in helical axis can be induced by
changes in glycosidic torsion angles of GlcA containing
GAG backbone in the case of heparan and chondroitin
sulfate. Nevertheless, the IdoA in HSGAGs and derma-
tan sulfate would provide additional conformational
flexibility to the GAG backbone and thus influence the
degree of the kink. It is important to note that the motif
that spans the kink is a high-energy structure since it is
a sharp bend or overwind of the otherwise low-energy
helical structure. Thus, from an energetics standpoint,
unbound GAG oligosaccharides would not favor the
formation of kink. The internal steric energy of the kink
spanning motif is compensated by the favorable van
der Waals and ionic contact energy with the binding
site of the protein [53]. On the protein side, the topology
of the binding site and distribution of basic residues in
the binding site provide structural constraints on the
GAG oligosaccharide.
The structural signature based on the kink provides
a framework for understanding the specificity of GAG-
protein interactions in terms of GAG sequence and how
that impinges on the function of the protein. For in-
stance, the kink in the FGF bound HSGAG oligosaccha-
rides provided a framework to interpret the graded
affinities of a library of heparan sulfate-derived oligo-
saccharides to FGF-1 and FGF-2 published in a recent
study [59]. The propensity of the oligosaccharides to
form the trisaccharide spanning kink [HNS,6S-I2S-HNS,6S]
correlated well with their low-, moderate-, and high-
affinity binding to FGF-1 (Figure 4). Thus by determining
the frequency of trisaccharide sequence motifs that
can potentially form the kink, it is possible to qualita-
tively assign the affinity of any oligosaccharide to FGF-1
and FGF-2. The kink in oligosaccharide chains has also
been observed in other polysaccharides. The cocrystal
structure study of pectate lyase with its pectate sub-
strate indicates a local deviation in the helical symme-
try of the substrate from 31 to 21 at the catalytic site of
the enzyme [60].
Intriguing and Challenging Aspects of GAG
Structure-Function Relationships
The examples discussed above show that understand-
ing the relationship between GAG sequence, its spe-
cific interaction with proteins, and how that modulates
protein function is both a fascinating as well as chal-
lenging area of research.Figure 4. Affinity to FGF Reflected on Propensity of Kink Formation
Shown from top to bottom are schematic representations of hepa-
rin oligosaccharide sequences with high to moderate to low affinity
for FGF-1 [43] where the kink is represented as a bulge. For each
oligosaccharide, there are two possible orientations (shown on left
and right) of the sulfate groups relative to the helical axis (up or
down) that account for the 2-fold helical symmetry of heparin. The
critical sulfate groups interacting with FGF are shown in red.Unlike DNA, RNA, or proteins, the biosynthesis of
complex polysaccharides like GAGs is a nontemplate-
driven process involving several enzymes and their tis-
sue-specific isoforms. The complexity of the biosyn-
thetic machinery complicates the understanding of
structure-function relationships. Due to the nontem-
plate-driven biosynthesis, it is difficult to amplify spe-
cific GAG oligosaccharides such as those containing
AT-III binding pentasaccharide, which are known to play
important biological roles. Further, the redundancy of
the biosynthetic machinery based on different enzyme
isoforms makes it challenging to take a functional ge-
nomics approach by knocking in or knocking out spe-
cific biosynthetic enzymes in order to understand the
effect of a specific sulfation pattern in vivo.
Given that GAGs modulate the biological roles of pro-
teins by facilitating the formation of protein-protein
complexes, it is obvious that the relative locations of
different molecular recognition motifs in the context of
overall chain length of the GAGs are important determi-
nants of their structure-function relationships. This fur-
ther adds to the challenges to just isolating and identi-
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276fying oligosaccharide motifs with high binding affinity
to a single protein. As discussed in the examples
above, it is evident that even in terms of affinity it is not
always the case where only high-affinity GAG-protein 1
interactions produce biologically significant responses.
This is particularly applicable to growth and develop-
1mental processes where a gradient of protein concen-
tration is necessary for the required biological out-
come. Taken together, it is clear that by contrasting the
role of GAG-protein interactions with other biomolecu-
lar interactions such as DNA-protein and protein-pro- 1
tein interactions, the former provides an “analog”
means to modulate protein function while latter pro-
vides a “digital” means to completely switch on or
switch off the activity of the protein. Thus, understand- 1
ing the structure-function relationships of GAGs could
provide a framework for developing novel approaches
1for therapeutic intervention in diseases such as cancer,
cardiovascular, and those related to microbial patho-
genesis. 1
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